Journal of Transplantation / 2012 / Article / Tab 2 / Clinical Study
A Prospective, Multinational Pharmacoepidemiological Study of Clinical Conversion to Sirolimus Immunosuppression after Renal Transplantation Table 2 Mean (and SD) doses and blood levels of sirolimus and calcineurin inhibitors in subjects receiving these medications at specified time relative to conversion to sirolimus.
Conversion Month 3 Month 6 Year 1 Year 2 All subjects (
𝑛
=
4
8
4
) Sirolimus dose (mg/d) 4.3 ± 3.8 2.9 ± 2.1 2.8 ± 1.6 2.6 ± 1.5 2.3 ± 1.1 Sirolimus level (μ g/L) 5.4 ± 5.5 10.1 ± 4.6 9.3 ± 4.0 9.0 ± 3.8 8.5 ± 2.9 Tacrolimus dose (mg/d) 6.0 ± 4.1 5.4 ± 3.3 5.3 ± 2.8 5.3 ± 3.6 4.5 ± 2.2 Tacrolimus level (μ g/L) 7.3 ± 3.6 6.7 ± 3.8 5.8 ± 3.2 5.8 ± 2.5 5.0 ± 2.2 Cyclosporine dose (mg/d) 188 ± 183 181 ± 111 154 ± 107 128 ± 74 167 ± 107 Cyclosporine level (μ g/L) 194 ± 181 220 ± 129 186 ± 101 158 ± 91 159 ± 91 Converted early (
𝑛
=
1
8
7
) Sirolimus dose (mg/d) 4.3 ± 2.9 3.2 ± 2.6 2.8 ± 1.6 2.7 ± 1.8 2.1 ± 0.7 Sirolimus level (μ g/L) < 1 yr 8.4 ± 5.9 10.4 ± 4.6 9.7 ± 4.0 9.0 ± 4.0 8.4 ± 3.1 Tacrolimus dose (mg/d) 7.5 ± 5.7 6.9 ± 4.4 6.4 ± 3.5 7.0 ± 4.7 5.5 ± 2.7 Tacrolimus level (μ g/L) 8.7 ± 4.0 7.1 ± 3.8 6.5 ± 3.8 6.1 ± 2.5 6.0 ± 3.2 Cyclosporine dose (mg/d) 283 ± 309 220 ± 148 186 ± 155 130 ± 92 NS Cyclosporine level (μ g/L) 270 ± 237 204 ± 137 120 ± 60 99 ± 63 88 ± 46 Converted late (
𝑛
=
2
9
7
) Sirolimus dose (mg/d) 4.3 ± 4.4 2.7 ± 1.7 2.7 ± 1.6 2.6 ± 1.3 2.4 ± 1.2 Sirolimus level (μ g/L) > 1 yr 4.1 ± 4.8 10.5 ± 4.6 9.7 ± 4.0 9.0 ± 4.0 8.4 ± 3.1 Tacrolimus dose (mg/d) 4.7 ± 2.1 4.5 ± 2.0 4.5 ± 1.8 4.1 ± 1.9 4.0 ± 1.7 Tacrolimus level (μ g/L) 6.1 ± 2.6 6.3 ± 3.8 5.3 ± 2.7 5.6 ± 2.5 4.4 ± 1.0 Cyclosporine dose (mg/d) 157 ± 99 150 ± 56 140 ± 79 128 ± 72 167 ± 107 Cyclosporine level (μ g/L) 184 ± 172 225 ± 127 120 ± 66 99 ± 63 88 ± 46